IRulya Therapeutics Overview

  • Year Founded
  • 2012

Year Founded

  • Status
  • Public

  • Employees
  • 38

Employees

  • Stock Symbol
  • IRLA

Stock Symbol

  • Investments
  • 3

  • Share Price
  • $39.88
  • (As of Friday Closing)

IRulya Therapeutics General Information

Description

IRulya Therapeutics Inc is committed to transforming the lives of patients with serious, underserved diseases by developing disease-modifying therapies. The company is currently developing LAM-001 for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD), bronchiolitis obliterans syndrome post-lung transplant (BOS), and sarcoidosis-associated pulmonary hypertension (SAPH). A Phase 2a study in PH patients has been completed; a Phase 2 clinical study in BOS patients is ongoing; a Phase 2b clinical study in PH-ILD is ongoing; and a Phase 2 clinical study in SAPH is ongoing.

Contact Information

Website
www.irulya.com
Formerly Known As
Cortexyme, Quince Therapeutics
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 101 College Street
  • Suite 210
  • New Haven, CT 06510
  • United States
+1 (415)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • 101 College Street
  • Suite 210
  • New Haven, CT 06510
  • United States
+1 (415)

IRulya Therapeutics Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

IRulya Therapeutics Stock Performance

As of 20-Nov-2026, IRulya Therapeutics’s stock price is $39.88. Its current market cap is $432M with 10.8M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$39.88 $40.07 $15.10 - $909.98 $432M 10.8M 62.2K -$162.19

IRulya Therapeutics Financials Summary

As of 30-Sep-2026, IRulya Therapeutics has a trailing 12-month revenue of null.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 59,369 178,238 49,886 (38,152)
Revenue 0 0 0 0
EBITDA (111,063) (81,867) (59,484) (34,738)
Net Income (106,778) (83,979) (56,828) (31,385)
Total Assets 106,472 93,523 114,478 167,900
Total Debt 0 18,471 14,811 13,814
Public Fundamental Data provided by Morningstar, Inc. disclaimer

IRulya Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore IRulya Therapeutics‘s full profile, request access.

Request a free trial

IRulya Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore IRulya Therapeutics‘s full profile, request access.

Request a free trial

IRulya Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
IRulya Therapeutics Inc is committed to transforming the lives of patients with serious, underserved diseases by develop
Drug Discovery
New Haven, CT
38 As of 2025

Carlsbad, CA
 

Plymouth Meeting, PA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

IRulya Therapeutics Competitors (135)

One of IRulya Therapeutics’s 135 competitors is Design Therapeutics, a Formerly VC-backed company based in Carlsbad, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Design Therapeutics Formerly VC-backed Carlsbad, CA
Harmony Biosciences Holdings Formerly VC-backed Plymouth Meeting, PA
Rein Therapeutics Formerly VC-backed Austin, TX
Tenax Therapeutics Formerly VC-backed Chapel Hill, NC
Inovio Pharmaceuticals Corporation Plymouth Meeting, PA
You’re viewing 5 of 135 competitors. Get the full list »

IRulya Therapeutics Patents

IRulya Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2025158249-A1 Intra-erythrocyte dexamethasone for treatment of ataxia-telangiectasia Pending 25-Jan-2024
AU-2023217975-A1 Variants of the human atm protein for the treatment of diseases related to at least one mutation of the atm gene Inactive 14-Feb-2022
EP-4479527-A1 Variants of the human atm protein for the treatment of diseases related to at least one mutation of the atm gene Inactive 14-Feb-2022
US-20250297235-A1 Variants of the human atm protein for the treatment of diseases related to at least one mutation of the atm gene Pending 14-Feb-2022
AU-2022279663-A1 Engineering new metabolic pathways in isolated cells for the degradation of guanidinoacetic acid and simultaneous production of creatine Inactive 27-May-2021 C12N9/1007
To view IRulya Therapeutics’s complete patent history, request access »

IRulya Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

IRulya Therapeutics Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore IRulya Therapeutics‘s full profile, request access.

Request a free trial

IRulya Therapeutics Acquisitions (3)

IRulya Therapeutics’s most recent deal was a Merger/Acquisition with OrphAI Therapeutics for . The deal was made on 18-May-2026.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
OrphAI Therapeutics 18-May-2026 Merger/Acquisition Drug Discovery
EryDel 20-Oct-2023 Merger/Acquisition Drug Delivery
Novosteo 19-May-2022 Merger/Acquisition Pharmaceuticals
To view IRulya Therapeutics’s complete acquisitions history, request access »

IRulya Therapeutics ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

35.2 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,592

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Biotechnology

Subindustry

of 431

Rank

Percentile

To view IRulya Therapeutics’s complete esg history, request access »

IRulya Therapeutics Exits (1)

IRulya Therapeutics’s most recent exit was on 20-Oct-2023 from EryDel. The exit was categorized as .

Company Name Exit Date Exit Type Exit Size Status Buyers
EryDel 20-Oct-2023 Completed
To view IRulya Therapeutics’s complete exits history, request access »

IRulya Therapeutics FAQs

  • When was IRulya Therapeutics founded?

    IRulya Therapeutics was founded in 2012.

  • Where is IRulya Therapeutics headquartered?

    IRulya Therapeutics is headquartered in New Haven, CT.

  • What is the size of IRulya Therapeutics?

    IRulya Therapeutics has 38 total employees.

  • What industry is IRulya Therapeutics in?

    IRulya Therapeutics’s primary industry is Drug Discovery.

  • Is IRulya Therapeutics a private or public company?

    IRulya Therapeutics is a Public company.

  • What is IRulya Therapeutics’s stock symbol?

    The ticker symbol for IRulya Therapeutics is IRLA.

  • What is the current stock price of IRulya Therapeutics?

    As of 20-Nov-2026 the stock price of IRulya Therapeutics is $39.88.

  • What is the current market cap of IRulya Therapeutics?

    The current market capitalization of IRulya Therapeutics is $432M.

  • Who are IRulya Therapeutics’s competitors?

    Design Therapeutics, Harmony Biosciences Holdings, Rein Therapeutics, Tenax Therapeutics, and Inovio Pharmaceuticals are some of the 135 competitors of IRulya Therapeutics.

  • What is IRulya Therapeutics’s annual earnings per share (EPS)?

    IRulya Therapeutics’s EPS for 12 months was -$162.19.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process